TAK-659 + lenalidomide

TAK-659 + lenalidomide is an investigational oral combination therapy for hematologic malignancies. TAK-659 is a **dual inhibitor of spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3)**[1][2], being explored for its targeted anti-tumor effects in B-cell lymphomas and other cancers. Lenalidomide is an **immunomodulatory agent and anti-neoplastic** used for multiple myeloma, lymphoma, and other hematologic neoplasms, which modulates the immune system, enhances T-cell and NK-cell activity, and has direct anti-tumor effects. The combination is studied for potential synergistic anti-cancer activity, primarily in relapsed/refractory lymphomas and other hematologic cancers[5].

Other names

TAK-659 plus lenalidomideTAK659 plus lenalidomideTAK 659 plus lenalidomide